| 1 |
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
|
| 2 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 3 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
|
| 4 |
Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016[J]. Ca A Cancer J Clin, 2016, 66(4): 271-289.
|
| 5 |
Listed N. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials: Non-small Cell Lung Cancer Collaborative Group[J]. BMJ, 1995, 311(7010): 899-909.
|
| 6 |
Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(9): 849-861.
|
| 7 |
Mok TS, Wu YS. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. New Engl J Med, 2009, 361(10): 10-12.
|
| 8 |
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. New Engl J Med, 2010, 362(25): 2380-2388.
|
| 9 |
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(2): 121-128.
|
| 10 |
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3): 239-246.
|
| 11 |
Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-342.
|
| 12 |
Yu HA. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J]. Clin Cancer Res, 2013, 19(8): 2240-2247.
|
| 13 |
Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors[J]. Clin Cancer Res, 2006, 12(21): 6494-6501.
|
| 14 |
Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med, 2017, 376(7): 629-640.
|
| 15 |
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
|
| 16 |
Presta LG, Chen H, O′connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders[J]. Cancer Res, 1997, 57(20): 4593.
|
| 17 |
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with Bevacizumab for non-small-cell lung cancer[J]. New Engl J Med, 2006, 355(24): 2542.
|
| 18 |
Scagliotti G, Novello S, Von Pawel J, et al. Phase Ⅲ study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(11): 1835-1842.
|
| 19 |
Paz-Ares LG, Biesma B, Heigener D, et al. Phase Ⅲ，randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2012, 30(25): 3084-3092.
|
| 20 |
Paz-Ares L, Hirsh V, Zhang L, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) Trial[J]. J Thorac Oncol, 2015, 10(12): 1745-1753.
|
| 21 |
Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(17): 2070-2078.
|
| 22 |
Ellis PM. Anti-angiogenesis in personalized therapy of lung cancer[J]. Adv Exp Med Biol, 2016, 893: 91-126.
|
| 23 |
Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1[J]. Gene, 2018, 654: 77-86.
|
| 24 |
Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib，a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018, 109(4): 1207-1219.
|
| 25 |
Han B, Li K, Wang Q, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncology, 2018, 4(11): 1569-1575.
|
| 26 |
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy：a new paradigm for combination therapy[J]. Nat Med, 2001, 7(9): 987.
|
| 27 |
Sorensen AG, Emblem KE, Polaskova P, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion[J]. Cancer Res, 2012, 72(2): 402-407.
|
| 28 |
Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study[J]. Lancet Oncol, 2014, 15(11): 1236-1244.
|